McKinsey & Co. will pay $650 million in penalties to the U.S. Department of Justice (DOJ) to settle charges that it advised Purdue Pharma on how to “turbocharge” the sale of Oxycontin in the middle of the U.S. opioid crisis.

McKinsey’s settlement with the DOJ also covered False Claims Act violations related to advising Purdue to submit false and fraudulent claims to federal healthcare programs for medically unnecessary prescriptions of Oxycontin, as well as for failing to disclose conflicts of interest the firm had when it was advising Purdue, and the U.S. Food and Drug Administration, on related matters at the same time.

The DOJ said that it also charged former McKinsey senior partner Martin Elling with obstructing their investigation when he attempted to destroy company documents related to the firm’s consultant work for Purdue. The DOJ later recovered the deleted documents during a forensic investigation of the company’s electronic records. Elling, who currently lives in Thailand, has agreed to plead guilty and will appear in court at a later date.